Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$40.48−0.52 (-1.26%)

Close on Nov 13, 2026Market cap $3.92BP/E –Yield –

Xenon Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Xenon Pharmaceuticals's EV/EBITDA was 11.3× on Oct 30, 2015.

Period	Period end	Value	Change (pts)
2015	Oct 30, 2015	11.3×	–

Parsed from the XBRL in Xenon Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XENE.

Revenue growth-100.0% · median -19.1%

Advertisement
300 × 250

See a number that looks wrong?